Palliative systemic therapy for young women with metastatic breast cancer.

Related Articles

Palliative systemic therapy for young women with metastatic breast cancer.

Curr Opin Support Palliat Care. 2015 Sep;9(3):301-7

Authors: Eng LG, Dawood S, Dent R

Abstract
PURPOSE OF REVIEW: Breast cancer in young women age less than 40 years remains a relatively rare disease. Emerging data suggest that the biology of breast cancer in younger women may differ from that of older women. Although metastatic breast cancer remains incurable, it is definitely treatable; especially in this era of emerging novel therapeutics.
RECENT FINDINGS: Most women have hormone receptor-positive disease and strategies that interfere with proliferation and the PI3 kinase pathway are reporting exciting results. The prognosis of the metastatic HER2 subtype has been extended to a median survival of 56 months with dual HER2 targeting agents in the first-line setting. Finally, triple negative breast cancer has an enlarging range of therapeutic options including immunotherapy, antiangiogenesis therapy, and targeted therapies including agents that interfere with androgen receptor signaling.
SUMMARY: Combined palliative and holistic approaches are essential to help young women navigate the marathon of treatment for metastatic breast cancer.

PMID: 26155021 [PubMed - indexed for MEDLINE]

from Head and Neck on PubMed via xlomafota13 on Inoreader http://ift.tt/1TlwJsJ


from #Med Blogs by Alexandros G.Sfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/1rWixPZ
via IFTTT